Trial Condition(s):

Atrial Fibrillation

Study of major cardiovascular events in patients with nonvalvular atrial fibrillation treated with Rivaroxaban (EMIR)

Bayer Identifier:

18884

ClinicalTrials.gov Identifier:

NCT02975453

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain

Inclusion Criteria
- Adult patients aged 18 years or older.
- Patients with diagnosis of NVAF.
- Patients treated with rivaroxaban from at least six months prior to the study inclusion.
- Patients who have been given appropriate information about the study objectives and procedures and who have given their written informed consent.
Exclusion Criteria
- Patients participating in an investigational program with interventions outside of routine clinical practice.
- Patients who initiate treatment with rivaroxaban after the start of the study inclusion period.
- Prosthetic heart valves or the presence of any severe valvulopathies. 
- Patients with severe cognitive impairment.
- Patients with chronic infections (HIV infection, hepatitis C virus, hepatitis B virus) or systemic autoimmune diseases.
- Patients with active cancer.
- Patients with liver insufficiency (eg. cirrhosis).

Trial Summary

Enrollment Goal
1481
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Spain

Status
Completed
 

Trial Design